Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Na-GST-1/Alhydrogel With TLR Agonists in Hookworm-Naïve Adults
NCT03172975Phase 2Completed
- Sponsor
- Baylor College of Medicine
- Start
- Mar 2018
- Primary completion
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Na-GST-1/Alhydrogel in hookworm infection (4 arms), sponsored by Baylor College of Medicine. Primary endpoints: Detectable Hookworm Infection at Day 280, Incidence of Serious Adverse Events and 6 more. Started Mar 2018; status: completed.
02
Drugs
Na-GST-1/Alhydrogel
03
Conditions
hookworm infection
Beyond the preview
Go deeper on NCT03172975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03172975.